Year: 2018
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions. METHODS: The electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined. RESULTS: OCD prevalence was 47%, higher in patients on poly-pharmacy than on monotherapy (64% vs 31%; p = 0.001). Two OCI-R factors had significantly higher scores and distinct risk factors: checking behaviour (mean = 5.1; SD = 3.6) correlated with length of clozapine treatment (r = 0.21; p = 0.026), and obsessing factor (mean = 4.8; SD = 3.6) correlated with psychosis severity (r = 0.59; p = 0.001). These factors along with total OCI-R, did not correlate with either clozapine dose or plasma levels, after correcting for psychosis severity. CONCLUSIONS: Screening for OCD in clozapine patients, and probably in those treated with structurally similar drugs with potent antiserotoninergic properties, should be widely adopted by clinicians. Further research is needed to understand the pathophysiology underlying repetitive behavior onset in clozapine-treated patients.
Source: Psychological Medicine
Institutions: University of Cambridge, Centro de Investigación Biomédica en Red de Salud Mental, Cambridgeshire and Peterborough NHS Foundation Trust, Sorbonne Université, Hôpital Saint-Antoine, Institut du Cerveau, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,726
Funders: Pfizer, Wellcome Trust, FORUM Pharmaceuticals, National Institute for Health and Care Research, European Commission, Generalitat de Catalunya, Fondation pour la Recherche Médicale, Centro de Investigación Biomédica en Red de Salud Mental, Servier, H. Lundbeck A/S, Medical Research Council, Cilag
OpenAlex ID: W2787477845
